Given the ever-advancing development of new pharmacological agents to treat heart conditions, clinicians could use a practical report on newly available treatments. The authors here address that need, profiling every pharmacological therapy in use to date for the treatment of heart failure. Renowned as experts in the field, these prominent academicians give incisive commentary on the state-of-the-art in heart failure, as their text is based on their personal experience with these drugs. Heart Failure Updates is a practical, information-packed reference that is essential for cardiologists, cardiac surgeons and associated specialists, particularly clinical biochemists, clinical pharmacologists, and epidemiologists.
Table of Contents
Anticytokine Therapy: What Went Wrong?
Heart Failure Due to Diastolic Dysfunction: Definition, Diagnosis and Treatment
Omaptrilat: The Potential of Vasopeptidase Inhibition
Angiotensin Receptor Blockers: ELITE, ValHEFT and Where Next?
Atrial Fibrillation and Heart Failure: Aetiological, Prognostic and Therapeutic Considerations
Endothelin Receptor Antagonists: Will They Join the Therapeutic Armamentarium?
Betablockers: Mandatory for All?
Aldosterone Receptor Blockade: Is There an Opportunity for Further Blockade in Patients with Heart Failure Treated with Standard Therapy Including an ACE-Inhibitor and a Beta Adrenergic Blocking Agent?
Nurse Intervention: Can Our Patients Do Without It?
Innovative Surgery: A New Dawn in Heart Failure?
The Era of Devices? Biventricular Pacing and ICDs
New Treatments for Heart Failure: Successes and Failures
Metabolic Co-morbid Conditions in Chronic Heart Failure: Diabetes and Hypercholesterolemia
BNP: A Blood Test for the Diagnosis of Heart Failure and Monitoring of Its Treatment?
John JV McMurray, MD, FRCP
Professor of Medical Cardiology
Honorary Consultant Cardiologist
And MRC Clinical Research Initiative in Heart Failure
University of Glasgow
Marc A Pfeffer, MD, PhD
Brigham and Women's Hospital
Boston MA, USA